Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (2)
P 2 (1)

Trial Status

Recruiting5
Not Yet Recruiting2

Clinical Trials (7)

Showing 7 of 7 trials
NCT07536841Not Yet Recruiting

Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Autoimmune Pancreatitis.

NCT07104058Not ApplicableRecruitingPrimary

A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD

NCT06978647Phase 1Recruiting

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

NCT06285279Phase 1Recruiting

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

NCT06696027Recruiting

AYLo - AutoimmunitY and Loss of y

NCT06794008Phase 2Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06655831Not Yet RecruitingPrimary

Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease

Showing all 7 trials

Research Network

Activity Timeline